Page last updated: 2024-09-03

ra 642 and Alloxan Diabetes

ra 642 has been researched along with Alloxan Diabetes in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
de la Cruz, JP; García-Campos, J; Mérida, F; Moreno, A; Sánchez de la Cuesta, F1
De La Cruz, JP; García Campos, J; Mérida, F; Moreno, A; Sánchez de la Cuesta, F1

Other Studies

2 other study(ies) available for ra 642 and Alloxan Diabetes

ArticleYear
The pyrimido-pyrimidine derivatives, dipyridamole and RA-642, reduce opacification of crystalline lens in diabetic rats.
    Pharmacology & toxicology, 1994, Volume: 75, Issue:5

    Topics: Animals; Blood Glucose; Cardiotonic Agents; Cataract; Diabetes Mellitus, Experimental; Dipyridamole; Lens, Crystalline; Lipid Peroxidation; Male; Malondialdehyde; Mopidamol; Pyrimidines; Rats; Rats, Wistar; Superoxides

1994
The pyrimido-pyrimidine derivatives, dipyridamole, mopidamol and RA-642, prevent from retinal vascular defects in experimental diabetes mellitus.
    Thrombosis research, 1996, Feb-01, Volume: 81, Issue:3

    Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Dipyridamole; Epoprostenol; Male; Mopidamol; Neovascularization, Pathologic; Platelet Aggregation Inhibitors; Pyrimidines; Rats; Rats, Wistar; Thromboxanes

1996